Medicare

Lightbeam Health Solutions Acquires Syntax Health, Expanding Value Based Contracting and Incentive Design Capabilities

Acquisition strengthens Lightbeam's AI-enabled operating system for value-based care by integrating Syntax's innovative incentive modeling platform and adds actuarial servicesDALLAS,...

Mynd Immersive and Select Rehabilitation Expand Partnership to 500+ Senior Care Communities, Establishing the Largest Immersive Therapeutics Dataset in U.S. Healthcare

Partnership brings MyndXR™ to over 150,000 residents, demonstrating how AI and spatial computing are defining the future of immersive healthcareDALLAS,...

Natus announces FDA 510(k) clearance for electrographic status epilepticus diagnostic indication in BrainWatch point-of-care EEG solution

MIDDLETON, Wis., Dec. 3, 2025 /PRNewswire/ -- Natus Medical Incorporated announced the electrographic status epilepticus diagnosis capability of its BrainWatch point-of-care...

CMS Finalizes OPPS Payment for Eko Health’s SENSORA® Platform, Expanding Reimbursement for AI-Enabled Cardiac Disease Detection in Hospital-Associated Outpatient Care

Final rule establishes national reimbursement under OPPS for AI-assisted cardiac analysis, enabling earlier cardiac disease detection in routine outpatient careSAN...

As UnitedHealthcare Scales Back Traditional RPM, Addison(R) Virtual Caregiver Signals the Next Phase of Home-Based Care

Electronic Caregiver's 24/7 virtual caregiving platform steps forward just as payers move away from low-engagement, device-only monitoring. LAS CRUCES, NM...

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025

BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug...

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision...

error: Content is protected !!